Video-Tumorboard PLUS

Launched by UNIVERSITY HOSPITAL MUENSTER · May 16, 2025

Keywords

ClinConnect Summary

The Video-Tumorboard PLUS clinical trial is designed to improve how patients with malignant melanoma receive expert cancer care through a virtual system. In this trial, doctors from different specialties meet weekly to discuss and recommend personalized treatment plans for patients, allowing individuals to benefit from a wide range of expert opinions without needing to travel to a specific location. This means that even if you live far away from top cancer centers, you can still access quality care tailored to your specific needs.

To participate in the trial, you need to be at least 18 years old and have a diagnosis of certain types of malignant melanoma or other related skin cancers. You also need to agree to join the study by signing a consent form. If you have complex cases or have been treated previously at another clinic, you may still be eligible. Throughout the trial, you can expect to be involved in a process that connects you with various specialists who will work together to develop the best treatment plan for you. This trial aims to make expert cancer treatment more accessible and inclusive for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
• Inclusion criteria for patients:
• • Minimum age 18 years
• * Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
• • Malignant melanoma from stage IIB
• • Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
• • In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
• Inclusion criteria for external doctors:
• • has a medical license
• • has dermatological patients who are eligible to be presented in the vTB+
• Exclusion Criteria:
• Patients will be excluded from the study if they meet the following criteria:
• • Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
• • No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.